Woods J, Sokhela S, Akpomiemie G, Bosch B, et al. DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy. HIV Med 2024 Sep 17. doi: 10.1111/hiv.13711.
PMID: 39286902